August 05, 2020

SK Pharmteco joins consortium to supply pharma ingredients in US

PUBLISHED : May 20, 2020 - 16:34

UPDATED : May 20, 2020 - 16:34

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

SK Pharmteco, a consolidated global pharmaceuticals manufacturing chain of SK Group, will provide US-based Phlow with pharmaceutical ingredients to offset supply shortfall in the country, SK Holdings announced on May 20.
The Donald Trump administration has announced it will buttress the project with $812 million funding over the next 10 years.

SK Holdings owns US’ Ampac Fine Chemicals and more contract manufacturing organization facilities in Europe and Korea. In January 2019, it established SK Pharmteco -- based in Sacramento, California -- a consolidated body of all its CMO facilities, to create synergies amongst its overseas manufacturing sites.

SK Pharmteco’s Virginia facility (SK Holdings)

From its facilities in Virginia and California, Ampac will supply Phlow with pharmaceutical ingredients for essential medicines in the US.

Phlow will use the pharmaceutical ingredients from Ampac to produce essential medicines for COVID-19 symptoms and also stock up on Strategic Active Pharmaceutical Ingredients Reserve, under the agreement with the Office of the Assistant Secretary for Preparedness and Response.

Generic drug distributor Civica and Virginia Commonwealth University’s Medicines for All Institute are also included in the consortium.

By Lim Jeong-yeo (

  • 페이스북
  • 트위터
  • sms
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099